Conditions: Atopic Dermatitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 98
Healthy volunteers: no

Brief summary:
This was a randomized, double blind, placebo controlled, parallel group study in approximately 90 subjects with moderate-severe AD Eczema Area and Severity Index (EASI) ≥12 and ≤ 48 (0-72 scale). Following a run-in subjects were randomized to receive either oral 30 mg ZPL-3893787 once daily (od) or placebo od for 8 weeks (56 days).

Detailed description:

Arms:
arm 1: 30 mg ZPL-3893787 orally once daily for 8 weeks. arm 2: 1 capsule orally once daily for 8 weeks.

Interventions: intervention 1: ZPL-3893787 intervention 2: Placebo
Intervention descriptions: intervention 1: ZPL-3893787 intervention 2: Matched Placebo

Protocol document: